These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 15947399

  • 1. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M, Richard H, Pilote L.
    BMJ; 2005 Jun 11; 330(7504):1370. PubMed ID: 15947399
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 11; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 11; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; 2002 Oct 11; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

  • 8. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 11; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 9. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May 11; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 12. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov 04; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 13. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN.
    Rheumatology (Oxford); 2007 Feb 04; 46(2):265-72. PubMed ID: 16844699
    [Abstract] [Full Text] [Related]

  • 14. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.
    Arthritis Res Ther; 2005 Feb 04; 7(2):R333-42. PubMed ID: 15743481
    [Abstract] [Full Text] [Related]

  • 15. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep 04; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 16. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM, Lévesque LE, Zhang B.
    Heart; 2007 Feb 04; 93(2):189-94. PubMed ID: 16849374
    [Abstract] [Full Text] [Related]

  • 17. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 18. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C, Wagner S.
    Clin Ther; 2003 Jan 27; 25(1):139-49. PubMed ID: 12637116
    [Abstract] [Full Text] [Related]

  • 19. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S, Spigset O, Slørdal L.
    Tidsskr Nor Laegeforen; 2005 Apr 07; 125(7):875-8. PubMed ID: 15815733
    [Abstract] [Full Text] [Related]

  • 20. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Apr 07; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.